Contact Information: For more information, please visit www.heponline.com. Contact information: Thomas D. Ingolia CEO Email Contact: 480-385-3800
Health Enhancement Products, Inc. Announces Teleconference to Discuss Clinical Trial Stoppage
| Source: Health Enhancement Products, Inc.
SCOTTSDALE, AZ,--(Marketwire - September 1, 2007) - Health Enhancement Products, Inc. (OTCBB : HEPI ), the maker of ProAlgaZyme®, will host a teleconference call on
Tuesday, September 4 at 9 AM Eastern Time, 6 AM Pacific Time, to discuss
the early termination of a trial of ProAlgaZyme in metabolic syndrome
patients in Minnesota. Interested listeners are invited to call
approximately 5 minutes ahead of time to (866) 814-1913. Please refer to
Conference ID 1136710, "Health Enhancement Products, Inc. Teleconference,"
moderator Tom Ingolia.
About Health Enhancement Products, Inc. and ProAlgaZyme
Health Enhancement Products Inc. is a nutraceutical company engaged in the
development of a supplementary health-enhancing product using only pure,
all-natural ingredients. The company's sole product is ProAlgaZyme, a
liquid product produced from algae grown in 100% distilled water. The
liquid in which the algae are grown is drawn off, filtered, tested and
bottled as ProAlgaZyme.
Except for any historical information, the matters discussed in this press
release contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements involve risks and
uncertainties. A number of factors could cause actual results to differ
from those indicated in the forward-looking statements, including the
timing of completion of a trial, actual future clinical trial results being
different than the results the company has obtained to date, our inability
to obtain regulatory approvals necessary to market and sell PAZ as a
pharmaceutical, and the company's ability to secure funding, including for
the subsidiary's pharmaceutical development of PAZ. Such statements are
subject to a number of assumptions, risks and uncertainties. Readers are
cautioned that such statements are not guarantees of future performance and
that actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements, whether
as a result of new information or otherwise.